85 related articles for article (PubMed ID: 8410287)
1. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy.
Hoekstra OS; Ossenkoppele GJ; Golding R; van Lingen A; Visser GW; Teule GJ; Huijgens PC
J Nucl Med; 1993 Oct; 34(10):1706-10. PubMed ID: 8410287
[TBL] [Abstract][Full Text] [Related]
2. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis.
Okada J; Yoshikawa K; Imazeki K; Minoshima S; Uno K; Itami J; Kuyama J; Maruno H; Arimizu N
J Nucl Med; 1991 Apr; 32(4):686-91. PubMed ID: 2013808
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy.
Delcambre C; Reman O; Henry-Amar M; Peny AM; Macro M; Cheze S; Génot JY; Tanguy A; Switsers O; Van HL; Couëtte JE; Leporrier M; Bardet S
Eur J Nucl Med; 2000 Feb; 27(2):176-84. PubMed ID: 10755723
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas.
Dimitrakopoulou-Strauss A; Strauss LG; Goldschmidt H; Lorenz WJ; Maier-Borst W; van Kaick G
Eur J Nucl Med; 1995 May; 22(5):434-42. PubMed ID: 7641752
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma.
Paul R
J Nucl Med; 1987 Mar; 28(3):288-92. PubMed ID: 3469332
[TBL] [Abstract][Full Text] [Related]
6. Aggressive non-Hodgkin lymphoma: early prediction of outcome with 67Ga scintigraphy.
Front D; Bar-Shalom R; Mor M; Haim N; Epelbaum R; Frenkel A; Gaitini D; Kolodny GM; Israel O
Radiology; 2000 Jan; 214(1):253-7. PubMed ID: 10644133
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor scintigraphy in malignant lymphoma: first results and comparison with glucose metabolism measured by positron-emission tomography.
Bares R; Galonska P; Dempke W; Handt S; Büll U; Osieka R
Horm Metab Res Suppl; 1993; 27():56-8. PubMed ID: 8330873
[TBL] [Abstract][Full Text] [Related]
8. Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography.
Hoekstra OS; van Lingen A; Ossenkoppele GJ; Golding R; Teule GJ
Eur J Nucl Med; 1993 Dec; 20(12):1214-7. PubMed ID: 8299657
[TBL] [Abstract][Full Text] [Related]
9. Bone lymphoma: 67Ga scintigraphy and CT for prediction of outcome after treatment.
Israel O; Mekel M; Bar-Shalom R; Epelbaum R; Hermony N; Haim N; Dann EJ; Frenkel A; Ben-Arush M; Gaitini D
J Nucl Med; 2002 Oct; 43(10):1295-303. PubMed ID: 12368366
[TBL] [Abstract][Full Text] [Related]
10. Ga-67 SPECT before and after treatment of lymphoma.
Front D; Israel O; Epelbaum R; Ben Haim S; Sapir EE; Jerushalmi J; Kolodny GM; Robinson E
Radiology; 1990 May; 175(2):515-9. PubMed ID: 2183289
[TBL] [Abstract][Full Text] [Related]
11. The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment.
Bar-Shalom R; Mor M; Yefremov N; Goldsmith SJ
Semin Nucl Med; 2001 Jul; 31(3):177-90. PubMed ID: 11430525
[TBL] [Abstract][Full Text] [Related]
12. [Tumor diagnosis using 18F-FDG SPECT].
Sugiyama S; Suzuki Y; Matsuzaki H; Tomiyoshi K; Endo K
Nihon Igaku Hoshasen Gakkai Zasshi; 1996 Aug; 56(9):679-80. PubMed ID: 8831228
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET for predicting the prognosis of malignant lymphoma.
Okada J; Oonishi H; Yoshikawa K; Itami J; Uno K; Imaseki K; Arimizu N
Ann Nucl Med; 1994 Aug; 8(3):187-91. PubMed ID: 7811561
[TBL] [Abstract][Full Text] [Related]
14. Camera-based FDG PET and 67Ga SPECT in evaluation of lymphoma: comparative study.
Bar-Shalom R; Yefremov N; Haim N; Dann EJ; Epelbaum R; Keidar Z; Gaitini D; Frenkel A; Israel O
Radiology; 2003 May; 227(2):353-60. PubMed ID: 12637679
[TBL] [Abstract][Full Text] [Related]
15. Residual mass and negative gallium scintigraphy in treated lymphoma.
Israel O; Front D; Epelbaum R; Ben-Haim S; Jerushalmi J; Kleinhaus U; Even-Sapir E; Robinson E
J Nucl Med; 1990 Mar; 31(3):365-8. PubMed ID: 2308008
[TBL] [Abstract][Full Text] [Related]
16. Fluorine-18 fluorodeoxyglucose positron emission tomography for lymphoma: incorporating new technology into clinical care.
Kaplan LD
Am J Med; 2002 Mar; 112(4):320-1. PubMed ID: 11893374
[No Abstract] [Full Text] [Related]
17. The continuing clinical role of gallium 67 scintigraphy in the age of receptor imaging.
Front D; Bar-Shalom R; Israel O
Semin Nucl Med; 1997 Jan; 27(1):68-74. PubMed ID: 9122725
[TBL] [Abstract][Full Text] [Related]
18. [Positron emission tomography of the thorax. The current clinical status].
Knopp MV; Bischoff H; Oberdorfer F; van Kaick G
Radiologe; 1992 Jun; 32(6):290-5. PubMed ID: 1641486
[TBL] [Abstract][Full Text] [Related]
19. Comparison of bone and 67Ga scintigraphy in the initial diagnosis of bone involvement in children with malignant lymphoma.
Mouratidis B; Gilday DL; Ash JM
Nucl Med Commun; 1994 Mar; 15(3):144-7. PubMed ID: 8190402
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity.
Okada J; Yoshikawa K; Itami M; Imaseki K; Uno K; Itami J; Kuyama J; Mikata A; Arimizu N
J Nucl Med; 1992 Mar; 33(3):325-9. PubMed ID: 1740697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
